The making and function of CAR cells
- PMID: 31181279
- PMCID: PMC7058416
- DOI: 10.1016/j.imlet.2019.06.002
The making and function of CAR cells
Abstract
Genetically engineered T cells expressing chimeric antigen receptors (CAR) present a new treatment option for patients with cancer. Recent clinical trials of B cell leukemia have demonstrated a response rate of up to 90%. However, CAR cell therapy is frequently accompanied by severe side effects such as cytokine release syndrome and the development of target cell resistance. Consequently, further optimization of CARs to obtain greater long-term efficacy and increased safety is urgently needed. Here we high-light the various efforts of adjusting the intracellular signaling domains of CARs to these major requirements to eventually obtain high-level target cell cytotoxicity paralleled by the establishment of longevity of the CAR expressing cell types to guarantee for extended tumor surveillance over prolonged periods of time. We are convinced that it will be crucial to identify the molecular pathways and signaling requirements utilized by such 'efficient CARs' in order to provide a rational basis for their further hypothesis-based improvement. Furthermore, we here discuss timely attempts of how to: i) control 'on-tumor off-target' effects; ii) introduce Signal 3 (cytokine responsiveness of CAR cells) as an important building-block into the CAR concept; iii) most efficiently eliminate CAR cells once full remission has been obtained. We also argue that universal systems for the variable and pharmacokinetically-controlled attachment of extracellular ligand recognition domains of choice along with the establishment of 'off-the-shelf' cell preparations with suitability for all patients in need of a highly-potent cellular therapy may become future mainstays of CAR cell therapy. Such therapies would have the attraction to work independent of the patients' histocompatibility make-up and the availability of functionally intact patient's cells. Finally, we summarize the evidence that CAR cells may obtain a prominent place in the treatment of non-malignant and auto-reactive T and B lymphocyte expansions in the near future, e.g., for the alleviation of autoimmune diseases and allergies. After the introduction of red blood cell transfusions, which were made possible by the landmark discoveries of the ABO blood groups by Karl Landsteiner, and the establishment of bone marrow transplantation by E. Donnall Thomas to exchange the entire hematopoietic system of a patient suffering from leukemia, the introduction of patient-tailored cytotoxic cellular populations to eradicate malignant cell populations in vivo pioneered by Carl H. June, represents the third major and broadly applicable milestone in the development of human cellular therapies within the rapidly developing field of applied biomedical research of the last one hundred years.
Keywords: Adoptive cell therapy; Cancer immunotherapy; Chimeric antigen receptor; Tumor microenvironment.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7058416/bin/EMS85543-f001.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7058416/bin/EMS85543-f002.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7058416/bin/EMS85543-f003.gif)
Similar articles
-
Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.Sci China Life Sci. 2018 Nov;61(11):1320-1332. doi: 10.1007/s11427-018-9411-4. Epub 2018 Nov 7. Sci China Life Sci. 2018. PMID: 30414005 Review.
-
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Front Immunol. 2018. PMID: 29515572 Free PMC article. Review.
-
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8. Mol Ther. 2019. PMID: 31005597 Free PMC article.
-
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23. Clin Cancer Res. 2018. PMID: 29061641 Free PMC article.
-
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Curr Res Transl Med. 2017. PMID: 28988742 Review.
Cited by
-
Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure.Chin Med J (Engl). 2023 Nov 20;136(22):2658-2667. doi: 10.1097/CM9.0000000000002904. Epub 2023 Nov 6. Chin Med J (Engl). 2023. PMID: 37927030 Free PMC article. Review.
-
CAR T-Cell therapy for the management of mantle cell lymphoma.Mol Cancer. 2023 Mar 31;22(1):67. doi: 10.1186/s12943-023-01755-5. Mol Cancer. 2023. PMID: 37004047 Free PMC article. Review.
-
Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.J Cancer Res Clin Oncol. 2023 Aug;149(10):7363-7378. doi: 10.1007/s00432-023-04683-5. Epub 2023 Mar 18. J Cancer Res Clin Oncol. 2023. PMID: 36933035 Free PMC article.
-
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.Mol Cell Biochem. 2023 May;478(5):967-980. doi: 10.1007/s11010-022-04568-0. Epub 2022 Oct 3. Mol Cell Biochem. 2023. PMID: 36190614 Review.
-
[Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells in vitro].Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jul 20;42(7):1062-1068. doi: 10.12122/j.issn.1673-4254.2022.07.15. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 35869771 Free PMC article. Chinese.
References
-
- Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245–1256. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources